The influence of Marjoram oil Extract (Origanum Vulgare) in treatment of chronic rhinosinusitis

Comparative evaluation of the influence of Marjoram oil Extract (Origanum Vulgare) in treatment of chronic rhinosinusitis without nasal polyps with fluticasone spray and sesame oil, concomitant with Life style modification of Traditional Persian Medicine, (a randomized, double-blind, clinical trial)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161022030439N2

Enrollment

Registered

2018-01-30

Start date

1991-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic sinusitis. Sinusitis (chronic) NOS

Interventions

Intervention 1: Prescribed in this group are:1- Marjoram oil nasal spray 2 puffs in each nostril Q12h for 4 wk. 2- Decosalin nasal spray 2 puffs Q12h for 4 wk. 3- Life style modification of Traditiona

Treatment - Drugs

Placebo

Prescribed in this group are:1- Marjoram oil nasal spray 2 puffs in each nostril Q12h for 4 wk. 2- Decosalin nasal spray 2 puffs Q12h for 4 wk. 3- Life style modification of Traditional Persian Medici

Prescribed in this group are: 1- Fluticasone nasal spray 2 puffs in each nostril Q12h for 4 wk. 2- Decosalin nasal spray 2 puffs Q12h for 4 wk. 3- Life style modification of Traditional Persian Medici

Prescribed in this group are: 1- Sesame oil nasal spray (placebo) 2 puffs in each nostril Q12h for 4 wk. 2- Decosalin nasal spray 2 puffs Q12h for 4 wk. 3- Life style modification of Traditional Persi

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- People with chronic sinusitis approved by the Academy of Otolaryngology-Head and Neck Ligation. This criteria contains the typical symptoms of chronic sinusitis, with or without appropriate medical treatment for more than 12 weeks. 2- Positive CT scan which indicates the opacity and swelling of the sinus mucosa. 3- Patients aged 18 to 60 years. 4- Fill the letter of satisfaction by the patient

Exclusion criteria

Exclusion criteria: Nose and sinus surgery in the last 5 years Antibiotic or topical corticosteroid use 15 days before entering the study Using oral corticosteroid 30 days before entering the study Moderate to severe asthma and mild asthma that has had an acute attack less than 30 days ago Aspirin- Exacerbated Respiratory Disease Active infections in the nose and sinuses Polyps in the nose Other diseases (neurogenic or psychiatric illness, malignancy, immunodeficiency) in the last 5 years, so that according to researcher, does not have the required qualifications to participate in the clinical trial Pregnancy

Design outcomes

Primary

Measure	Time frame
Cough. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Posterior nasal discharge. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Need to blow nose. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Sneezing. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Runny nose. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Nasal obstruction. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Loss of smell or taste. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Thick nasal discharge. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Post-nasal discharge. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Ear fullness. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Dizziness. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Ear pain. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Facial pain/pressure. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Difficulty falling asleep. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Waking up at night. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Lack of a good night’s sleep. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Waking up tired. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Exhausted feeling during day. Timepoi	—

Measure

Time frame

Cough. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Posterior nasal discharge. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Need to blow nose. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Sneezing. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Runny nose. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Nasal obstruction. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Loss of smell or taste. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Thick nasal discharge. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Post-nasal discharge. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Ear fullness. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Dizziness. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Ear pain. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Facial pain/pressure. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Difficulty falling asleep. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Waking up at night. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Lack of a good night’s sleep. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Waking up tired. Timepoint: Before and the end of the intervention. Method of measurement: SNOTE22 questionnaire.;Exhausted feeling during day. Timepoi

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyed Abdolreza Kamaneh

Gorgan University of Medical Sciences

dr.kamaneh@goums.ac.ir+98 17 3254 5923

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026